102 related articles for article (PubMed ID: 15169608)
1. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Rival Y; Benéteau N; Chapuis V; Taillandier T; Lestienne F; Dupont-Passelaigue E; Patoiseau JF; Colpaert FC; Junquéro D
DNA Cell Biol; 2004 May; 23(5):283-92. PubMed ID: 15169608
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.
Kintscher U; Goetze S; Wakino S; Kim S; Nagpal S; Chandraratna RA; Graf K; Fleck E; Hsueh WA; Law RE
Eur J Pharmacol; 2000 Aug; 401(3):259-70. PubMed ID: 10936484
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages.
Ringseis R; Schulz N; Saal D; Eder K
J Nutr Biochem; 2008 Sep; 19(9):594-603. PubMed ID: 18155510
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of MMP-9 activity in THP-1 cells by 7-ketocholesterol and its suppression by the HMG-CoA reductase inhibitor fluvastatin.
Ozaki H; Miyashita Y; Watanabe H; Shirai K
J Atheroscler Thromb; 2005; 12(6):308-14. PubMed ID: 16394614
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin.
Abe N; Osanai T; Fujiwara T; Kameda K; Matsunaga T; Okumura K
Life Sci; 2006 Jan; 78(9):1021-8. PubMed ID: 16182316
[TBL] [Abstract][Full Text] [Related]
6. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes.
Hua Y; Xue J; Sun F; Zhu L; Xie M
Pharmacology; 2009; 83(1):18-25. PubMed ID: 18971601
[TBL] [Abstract][Full Text] [Related]
7. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells.
Chuang SY; Yang SH; Chen TY; Pang JH
Eur J Pharmacol; 2011 Nov; 670(2-3):419-26. PubMed ID: 21925496
[TBL] [Abstract][Full Text] [Related]
9. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
Neve BP; Corseaux D; Chinetti G; Zawadzki C; Fruchart JC; Duriez P; Staels B; Jude B
Circulation; 2001 Jan; 103(2):207-12. PubMed ID: 11208678
[TBL] [Abstract][Full Text] [Related]
10. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.
Bellosta S; Via D; Canavesi M; Pfister P; Fumagalli R; Paoletti R; Bernini F
Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1671-8. PubMed ID: 9812903
[TBL] [Abstract][Full Text] [Related]
11. Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g.
Lee KJ; Kim HA; Kim PH; Lee HS; Ma KR; Park JH; Kim DJ; Hahn JH
Exp Mol Med; 2004 Dec; 36(6):534-44. PubMed ID: 15665586
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Cabrero A; Cubero M; Llaverías G; Jové M; Planavila A; Alegret M; Sánchez R; Laguna JC; Carrera MV
Metabolism; 2003 May; 52(5):652-7. PubMed ID: 12759900
[TBL] [Abstract][Full Text] [Related]
13. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.
Marx N; Sukhova G; Murphy C; Libby P; Plutzky J
Am J Pathol; 1998 Jul; 153(1):17-23. PubMed ID: 9665460
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells.
Bellosta S; Baetta R; Canavesi M; Comparato C; Granata A; Monetti M; Cairoli F; Eberini I; Puglisi L; Corsini A
Pharmacol Res; 2007 Aug; 56(2):160-7. PubMed ID: 17582780
[TBL] [Abstract][Full Text] [Related]
15. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid.
Worley JR; Baugh MD; Hughes DA; Edwards DR; Hogan A; Sampson MJ; Gavrilovic J
J Biol Chem; 2003 Dec; 278(51):51340-6. PubMed ID: 14534304
[TBL] [Abstract][Full Text] [Related]
16. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells.
Ikeda U; Shimpo M; Ohki R; Inaba H; Takahashi M; Yamamoto K; Shimada K
Hypertension; 2000 Sep; 36(3):325-9. PubMed ID: 10988259
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma.
Ge H; Zhang JF; Guo BS; He Q; Wang BY; He B; Wang CQ
Vascul Pharmacol; 2007 Feb; 46(2):114-21. PubMed ID: 17055343
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability.
Eberhardt W; Akool el-S; Rebhan J; Frank S; Beck KF; Franzen R; Hamada FM; Pfeilschifter J
J Biol Chem; 2002 Sep; 277(36):33518-28. PubMed ID: 12093797
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Llaverías G; Laguna JC; Alegret M
Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
